By SquaredTown on March 24, 2026
Funding will support clinical development of EPF-001, a first-in-class G9a inhibitor for sickle cell disease and beta thalassemia Company built on pioneering research from RIKEN and Tokyo University of Pharmacy and Life Sciences, with backing from leading Japanese venture capital firm...